文獻上記載明膠曾被用來當做製備藥物制放微粒載體的材料。但是過去的臨床經驗指出，明膠為一易溶於水且澎潤度相當高的水膠，因此以明膠包覆藥物的微粒載體，通常只能用於短效性的藥物制放。為了克服此一問題，臨床上常以formaldehyde或gluteraldehyde之類的化學交聯劑來交聯明膠微粒載體，藉以控制其澎潤度及水解速率，使得藥物能達到緩釋與長效的效果。但是formaldehyde及gluteraldehyde的細胞毒性太強，因此限制了明膠製成的微粒載體在臨床上的用途。為了解決這個問題，我們使用從中藥梔子果實裡萃取純化出來的一種天然交聯劑genipin，來交聯明膠製備藥物制放微粒載體。
本研究分別以體外實驗與體內實驗兩大部份，來評估以genipin交聯明膠製備藥物制放微粒載體(GP微粒載體)，當做肌肉注射劑型藥物制放的可行性。實驗?，我們的實驗對照組是以glutaraldehyde交聯明膠製備的藥物制放微粒載體(GA微粒載體)。體外實驗主要是探討以不同製備程序製備出來的GP微粒載體的表面形態、交聯程度及其粒徑大小與分佈情形，以找出製備GP微粒載體的較佳製程條件。較佳製程的選擇則是以以下幾個條件來判斷：(1)微粒表面光滑且不產生糾結的現象；(2)由於本研究希望能延長明膠微粒載體的水解時間，所以微粒載體的交聯程度將愈高愈好；(3)由於文獻上曾提及，理想的肌肉注射劑型微粒載體的粒徑大小約為20-100

1. Deasy, P.B., “Microencapsulation and related drug processes”, Marcel Dekker Inc., New York, 8-13, 1984.
2. Simpson, H., Mckinlay, I., “Poisoning with slow-release fenfluramine,” British Medical Journal, 4, 462-463, 1975.
3. 糜福龍，博士論文，中央大學化工所，1997.
4. Milovanoric, D., Norin, J.G., “Microencapsulation of sulfa draztine with cellulose acetate phthalate,” Drug Development Industry Pharmaceutics, 12, 1249-1258, 1986.
5. Hideo, T., Takashi, O., Masao, K., “Effect of polymer species on microencapsulation by a surface neutralization method,” Chemical and Pharmaceutical Bulletin, 40, 729-733, 1992.
6. Bechgaard, H., Cadefoged, K., “Gastrointestinal transit time of single-unit tablets,” Journal of Pharmacy and Pharmacology, 33, 791-792, 1981.
7. Sun, Y.M., Chang, C.C., Huang, W.F., Liang, H.C., “Fluidized-bed spray coated porous hydrogel beads for sustained release of diclofenac sodium,” Journal of Controlled Release, 47, 247-260, 1997.
8. Rao, K.P., “Recent developments of collagen-bases materials for medical applications and drug delivery system,” Journal of Biomaterials Science-Polymer Edition, 7, 623-645, 1995.
9. Leo, E., Vandelli, M.A., Cameroni, R., Forni, F., “Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: Involvement of the drug in the cross-linking process,” International Journal of Pharmaceutics, 155, 75-82, 1997.
10. Yan, C., Li, X., Chen, X., Wang, D., Zhong, D., Tan, T., Kitano, H., “Anticancer gelatin microspheres with multiple function,” Biomaterials, 12, 640-644, 1991.
11. Silvio, L.D., Gurav, N., Kayser, M.V., Braden, M., Downes, S., “Biodegradable microspheres: a new delivery system for growth hormone,” Biomaterials, 15, 931-936, 1994.
12. Rowe, J.S., Carless, J.E., “Comparison of the in vitro dissolution behaviour of various indomethacin formulations with their in vivo bioavailability,” Journal of Pharmacy and Pharmacology, 33, 561-564, 1981.
13. Chiao, C.S.L., Price, J.C., “Modification of gelatin beadlets for zero sustained release,” Pharmaceutical Research, 6, 517-520,1989.
14. Tabata, Y., Hijikata, S., Muniruzzaman, M., Ikada, Y., “Neovascularization effect of biodegradable gelation microspheres incorporating basic fibroblast growth factor,” Journal of Biomaterials Science-Polymer Edition, 10, 79-94, 1999.
15. Ratcliffe, J.H., Hunneyball, I.M., Smith, A., Wilson, C.G., Pavis, S.S., “Preparation and evaluation of biodegradable polymeric system for the intra-artitular delivery of drug,” Journal of Pharmacy and Pharmacology, 36, 431-436, 1984.
16. Nam, Y.S., Park, T.G., “Protein loaded Biodegradable microspheres bases on PLGA-protein bioconjugates,” Journal of Microencapsulation, 16, 625-637, 1999.
17. Sato, T., Kanke, M., Schroeder, H.G., Deluca, P.P., “Porous biodegradable microspheres for controlled drig delivery. I. Assessment of processing conditions and solvent removal techniques,” Pharmaceutical Research, 5, 21-30, 1988.
18. Jameela, S.R., Misra, A., Jayakrishnan, A., “Cross-linked chitosan microspheres as carriers for prolonged delivery of macromolecular drugs,” Journal of Biomaterials Science-Polymer Edition, 6, 621-632, 1994.
19. Jameela, S.R., Kumary, T.V., Lal, A.V., Jayakrishnan, A., “Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system,” Journal of Controlled Release, 52, 17-24, 1998.
20. Jayakrishnan, A., Jameela, S.R., “Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices,” Biomaterials, 17, 471-484, 1996.
21. Pavanetto, F., Genta, I., Giunchedi, P., Conti, B., Conte, U., “spray-dried albumin microspheres for the intra-articular delivery of dexamethasone,” Journal of Microencapsulation, 11, 445-454, 1994.
22. Esposito, E., Cortesi, R., Nastruzzi, C., “Gelatin microspheres: Influence of preparation parameters and thermal treatment on chemico-physical and biopharmaceutical properties,” Biomaterials, 17, 2009-2020, 1996.
23. Illum, L., Davis, S.S., Polymers in controlled drug delivery, Wright, Bristol, 73-86, 1987.
24. Nishi, C., Nakajima, N., Ikada, Y., “In vitro evaluation of cytotoxicity of diepoxy compounds used for biomaterial modification,” Journal of Biomedical Materials Research, 29, 829-834, 1995.
25. Hazel, B., Roy, O., Roy, G., “Formaldehyde as a pre-treatment for dermal collagen heterografts,” Biochimica et Biophysica Acta, 632, 589-597, 1980.
26. Gendler, E., Gendler, S., Nimni, M.E., “Toxic reactions evoked by glutaraldehyde-fixed pericardium and cardiac valve tissue bioprosthesis,” Journal of Biomedical Materials Research, 18, 727-736, 1984.
27. Speer, D.P., Chvapil, M., Eskelson, C.D., Ulreich, J., “Biological effects of residual glutaraldehyde in glutaraldehyde-tanned collagen biomaterials,” Journal of Biomedical Materials Research, 14, 753-764, 1980.
28. Huang-Lee, L.L.H., Cheung, D.T., Nimni, M.E., “Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks,” Journal of Biomedical Materials Research, 24, 1185-1201, 1990.
29. 陳永泰、陳建中及林昇鋒等人編譯，組織學，台北市，藝軒圖書出版社，1994，第十九章：348-349.
30. Fujikawa, S., Yokota, T., Koga, K., Kumada, S.I., “The continuous hydrolysis of geniposide to genpin using immobilized β-glucosidase on calcium alginate gel,” Biotechnology Letter, 9, 697-702, 1987.
31. Kimura, Y., Okuda, H., Archi, S., “Effects of geniposide isolated from Gardenia jasminoides on metabolic alterations in high sugar diet-fed rats,” Chemical and Pharmaceutical Bulletin, 30, 4444-4447, 1982.
32. Wang, C.J., Wang, S.W., Lin, J.K., “Suppressive effect of geniposide on the hepatotoxicity and hepatic DNA binding of aflatoxin B1 in rats,” Caner Letters, 60, 95-102, 1991.
33. Tseng, T.H., Chu, C.Y., Wang, C.J., “Inhibition of penta-acetyl geniposide on AFB1-induced genotoxicity in C3H10T1/2 cells,” Cancer Letters, 62, 233-242, 1992.
34. Miwa, T., Jap J Pharmacol., 2, 102-108, 1953.
35. Miwa, T., Jap J Pharmacol., 2, 139-143, 1953.
36. Miwa, T., Jap J Pharmacol., 3, 1-5, 1953.
37. Sung, H.W., Huang, R.N., Huang, L.L.H., Tsai, C.C., “In vitro evalualtion of cytotoxicity of a naturally occurring crosslinking reagent for biological tissue fixation,” Journal of Biomaterials Science-Polymer Edition, 13, 63-78, 1999.
38. Sung, H.W., Huang, R.N., Huang, L.L.H., Tsai, C.C., Chiu, C.T., “Feasibility study of a natural crosslinking reagent for biological tissue fixation,” Journal of Biomedical Materials Research, 42, 560-567, 1998.
39. Huang, L.L.H, Sung, H.W., Tsai, C.C., Huang, D.M., “Biocompatibility study of a biological tissue fixed with a naturally occuring crosslinking reagent,” Journal of Biomedical Materials Research, 42, 568-576, 1998.
40. 張文祥，碩士論文，中央大學化工所，1999.
41. Ugwoke, M.I., Kinget, R., “Influence of processing variables on the properties of gelatin microspheres prepared by emulsification solvent extraction technique,” Journal of Miicroencapsulation, 15, 273-281, 1998.
42. 梁義林，碩士論文，中央大學化工所，1999.
43. Silvestro, L., Viano, I., Macario, M., Colangelo, D., Montrucchio, G., Panico, S., and Fantozzi, R., “Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion,” Seminar in Thrombosis and Hemostasis, 20, 254-258, 1994.
44. Nimini, M.E., Cheung, D., Strate, B., Kodama, M., Sheikh, K., “Bioprosthesis derived from cross-linked and chemically modified collagenous tissues,” in collagen Vol.III, M.E., Nimini (ed.), CRC Press, Boca Raton, Florida; 1-38, 1988.
45. Sung, H.W., Huang, D.M., Chang, W.H., Huang, R.N., Hsu, J.C., “Evaluation of Gelatin Hydrogel Crosslinked with Various Crosslinking Agents as Bioadhesives: An In Vitro Study,” Journal of Biomedical Materials Research . 46, 520-530, 1999.
46. Robert, C.C.R., Buri, P.A., Peppas, N.A., “Influence of the drug solubility and dissolution medium on the release from poly(2-hydroxyethyl methacrylate) microspheres,” Journal of Controlled Release, 5, 151-157, 1987.
47. Vandelli, M.A., Forni, F., Coppi, G., Cameroni, R., “The effect of the cross-linking time period upon the drug release and the dynamic swelling of gelatin mictospheres,” Pharmazie, 46, 866-869, 1991.
48. Ritger, P.L., Peppas, N.A., “A simple equation for description of solute release Ⅱ fickian and anomalous release from swellable devices,” Journal of Controlled Release, 5, 37-42, 1987.
49. Gander, B., Gurny, R., Doelker, E., Peppas, N.A., “Crosslinked poly(alkylene oxides) for the preparation of controlled release micromatrices,” Journal of Controlled Release, 5, 271-283, 1988.
50. Leucuta, S.E., Ponchel, G., Duchene, D., “Dynamic swelling behaviour of gelatin / poly(acrylic acid) bioadhesive microspheres loaded with oxpreolol,” Journal of Microencapsulation, 14, 501-510, 1997.